MIM-D3 (Dry Eye Syndrome)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 12
3.1.3 Classification 14
3.1.4 Prognosis 14
3.1.5 Quality of Life 15
3.2 Symptoms 15
4 Disease Management 17
4.1 Overview 17
4.1.1 Diagnosis Overview 17
4.1.2 Treatment Guidelines 20
4.1.3 Treatment Overview 24
5 Competitive Assessment 27
5.1 Overview 27
5.2 Strategic Competitor Assessment 27
6 Opportunity and Unmet Need 29
6.1 Overview 29
6.2 Diagnostic tests are not specific enough to identify subgroups of patients 30
6.3 Frequent dosing and side effects limit compliance 31
6.4 Lack of physician and patient awareness 32
6.5 Trial design may be a factor in so few drugs being approved 33
6.6 Unmet Needs Gap Analysis 34
6.7 Comprehensive method for measuring dry eye signs and severity levels 35
6.8 Increase treatment rates among milder forms of the disease 36
7 Pipeline Assessment 37
7.1 Overview 37
7.2 Promising drugs in clinical development 38
8 MIM-D3 40
8.1 Overview 40
8.2 Efficacy 41
8.3 Safety 41
8.4 Dosing and Formulation 41
8.5 Potential Clinical Positioning 41
8.6 Potential Commercial Positioning 41
8.7 Pricing and Reimbursement 42
8.8 SWOT Analysis 43
8.9 Forecast 44
9 Appendix 45
9.1 Bibliography 45
9.2 Abbreviations 47
9.3 Methodology 49
9.4 Forecasting Methodology 49
9.4.1 Diagnosed DES patients 49
9.4.2 Percent Drug-treated Patients 50
9.4.3 General Pricing Assumptions 50
9.4.4 Individual Drug Assumptions 51
9.4.5 Generic Erosion 51
9.5 Physicians and Specialists Included in this Study 52
9.6 About the Authors 53
9.6.1 Author 53
9.6.2 Global Head of Healthcare 54
9.7 About GlobalData 55
9.8 Contact Us 55
9.9 Disclaimer 55